Context Therapeutics
CNTX· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock +40.0% in FY2025
Martin Lehr is the CEO of Context Therapeutics and was paid $1.5M in FY2025 (Dec), up 45%.
Pay$100 in the stock at the end of FY21 → $55
Executives3
See all- 1Martin LehrChief Executive OfficerFY2025
- 2Jennifer Minai-AzaryChief Financial Officer and TreasurerFY2025
- 3Alex LevitChief Legal Officer and Corporate SecretaryFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allContext Therapeutics paid its 3 named executives $3.1M in total in FY2025 (Dec). CEO Martin Lehr was paid $1.5M of that.
| Name | |||
|---|---|---|---|
| Martin LehrChief Executive Officer | |||
| Jennifer Minai-AzaryChief Financial Officer and Treasurer | |||
| Alex LevitChief Legal Officer and Corporate Secretary |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Context Therapeutics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board2
See all- Andy PasternakChair · 0 yr on the boardIndependentAudit, Compensation—Paid as an executive
- Luke Walker, MDDirector · 1 yr on the boardIndependentNominating and Corporate Governance—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 28, 2026 | FY2025 |
| Annual report | 10-K | Mar 23, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 15, 2025 | FY2024 |
| Annual report | 10-K | Mar 20, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 26, 2024 | FY2023 |
| Annual report | 10-K | Mar 21, 2024 | FY2023 |
